Amgen Inc. (NASDAQ:AMGN) Position Raised by International Private Wealth Advisors LLC

International Private Wealth Advisors LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 903 shares of the medical research company’s stock after purchasing an additional 63 shares during the quarter. International Private Wealth Advisors LLC’s holdings in Amgen were worth $235,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in Amgen in the 3rd quarter worth about $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the 3rd quarter worth approximately $29,000. Heck Capital Advisors LLC acquired a new position in Amgen during the fourth quarter valued at $36,000. Livelsberger Financial Advisory purchased a new stake in shares of Amgen in the third quarter worth approximately $56,000. Finally, Kennebec Savings Bank purchased a new stake in Amgen in the 3rd quarter worth approximately $57,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research reports. TD Cowen upped their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Citigroup dropped their target price on Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Redburn Partners reduced their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $314.09.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $294.79 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a market cap of $158.46 billion, a P/E ratio of 39.05, a P/E/G ratio of 3.01 and a beta of 0.56. The business’s 50 day moving average is $272.26 and its two-hundred day moving average is $302.77. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities analysts expect that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.23%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 119.21%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.69% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.